Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Shares Outstanding (Diluted Average) (2017 - 2025)

OptimizeRx (OPRX) has disclosed Shares Outstanding (Diluted Average) for 15 consecutive years, with $19.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 3.86% to $19.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.0 million through Dec 2025, up 3.86% year-over-year, with the annual reading at $19.0 million for FY2025, 3.86% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $19.0 million in Q4 2025 for OptimizeRx, down from $19.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $19.5 million in Q3 2025 to a low of $16.1 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $17.8 million across 5 years, with a median of $18.0 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 23.68% in 2021 and later dropped 7.47% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $17.7 million in 2021, then grew by 0.53% to $17.8 million in 2022, then decreased by 3.71% to $17.1 million in 2023, then rose by 6.82% to $18.3 million in 2024, then rose by 3.86% to $19.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for OPRX at $19.0 million in Q4 2025, $19.5 million in Q3 2025, and $18.5 million in Q2 2025.